{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:02:24Z","timestamp":1789761744443,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["personal grant no PZ00P3_179919"],"award-info":[{"award-number":["personal grant no PZ00P3_179919"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s15010-022-01821-y","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T06:02:35Z","timestamp":1650002555000},"page":"783-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series"],"prefix":"10.1007","volume":"50","author":[{"given":"Susanne","family":"R\u00fcfenacht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Gantenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Boggian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Flury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Dollenmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0427-8934","authenticated-orcid":false,"given":"Philipp","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner C.","family":"Albrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"1821_CR1","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00296-020-04699-x","volume":"40","author":"J Loarce-Martos","year":"2020","unstructured":"Loarce-Martos J, Garc\u00eda-Fern\u00e1ndez A, L\u00f3pez-Guti\u00e9rrez F, Garc\u00eda-Garc\u00eda V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40:2015\u201321. https:\/\/doi.org\/10.1007\/s00296-020-04699-x.","journal-title":"Rheumatol Int"},{"key":"1821_CR2","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","volume":"3","author":"J Avouac","year":"2021","unstructured":"Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3:e419\u201326. https:\/\/doi.org\/10.1016\/S2665-9913(21)00059-X.","journal-title":"Lancet Rheumatol"},{"key":"1821_CR3","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMc2031364","volume":"383","author":"B Choi","year":"2020","unstructured":"Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291\u20133. https:\/\/doi.org\/10.1056\/NEJMc2031364.","journal-title":"N Engl J Med"},{"key":"1821_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","volume":"222","author":"M Helleberg","year":"2020","unstructured":"Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech A-M, Lane C, Lundgren J. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222:1103\u20137. https:\/\/doi.org\/10.1093\/infdis\/jiaa446.","journal-title":"J Infect Dis"},{"key":"1821_CR5","doi-asserted-by":"publisher","first-page":"e789","DOI":"10.1016\/S2665-9913(21)00251-4","volume":"3","author":"MB Moor","year":"2021","unstructured":"Moor MB, Suter-Riniker F, Horn MP, Aeberli D, Amsler J, M\u00f6ller B, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. Lancet Rheumatol. 2021;3:e789\u201397. https:\/\/doi.org\/10.1016\/S2665-9913(21)00251-4.","journal-title":"Lancet Rheumatol"},{"key":"1821_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jaci.2021.10.031","volume":"149","author":"LAK Brown","year":"2022","unstructured":"Brown LAK, Moran E, Goodman A, Baxendale H, Bermingham W, Buckland M, et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2022;149:557-561.e1. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.031.","journal-title":"J Allergy Clin Immunol"},{"key":"1821_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04594-4","author":"S Iketani","year":"2022","unstructured":"Iketani S, Liu L, Guo Y, Liu L, Chan JF-W, Huang Y, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022. https:\/\/doi.org\/10.1038\/s41586-022-04594-4.","journal-title":"Nature"},{"key":"1821_CR8","unstructured":"Therapeutics and COVID-19: living guideline. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.2. Accessed 11 Mar 2022."},{"key":"1821_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med. 2020;383:1813\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","journal-title":"N Engl J Med"},{"key":"1821_CR10","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(20)31022-9.","journal-title":"Lancet"},{"key":"1821_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"RL Gottlieb","year":"2022","unstructured":"Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2116846.","journal-title":"N Engl J Med"},{"key":"1821_CR12","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","author":"VM Corman","year":"2020","unstructured":"Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.3.2000045.","journal-title":"Euro Surveill"},{"key":"1821_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijid.2021.02.092","volume":"106","author":"RM Mehta","year":"2021","unstructured":"Mehta RM, Bansal S, Bysani S, Kalpakam H. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: a real-world analysis. Int J Infect Dis. 2021;106:71\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2021.02.092.","journal-title":"Int J Infect Dis"},{"key":"1821_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12916-020-01810-8","volume":"18","author":"S Mallett","year":"2020","unstructured":"Mallett S, Allen AJ, Graziadio S, Taylor SA, Sakai NS, Green K, et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC Med. 2020;18:346. https:\/\/doi.org\/10.1186\/s12916-020-01810-8.","journal-title":"BMC Med"},{"key":"1821_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1474","author":"M Martinot","year":"2020","unstructured":"Martinot M, Jary A, Fafi-Kremer S, Leducq V, Delagreverie H, Garnier M, et al. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa1474.","journal-title":"Clin Infect Dis"},{"key":"1821_CR16","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ajh.26209","volume":"96","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, et al. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96:934\u201344. https:\/\/doi.org\/10.1002\/ajh.26209.","journal-title":"Am J Hematol"},{"key":"1821_CR17","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1007\/s00277-021-04662-1","volume":"100","author":"H Levavi","year":"2021","unstructured":"Levavi H, Lancman G, Gabrilove J. Impact of rituximab on COVID-19 outcomes. Ann Hematol. 2021;100:2805\u201312. https:\/\/doi.org\/10.1007\/s00277-021-04662-1.","journal-title":"Ann Hematol"},{"key":"1821_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac180","author":"LD Saravolatz","year":"2022","unstructured":"Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and nirmatrelvir-ritonavir: oral COVID antiviral drugs. Clin Infect Dis. 2022. https:\/\/doi.org\/10.1093\/cid\/ciac180.","journal-title":"Clin Infect Dis"},{"key":"1821_CR19","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood.2020008423","volume":"136","author":"T Hueso","year":"2020","unstructured":"Hueso T, Pouderoux C, P\u00e9r\u00e9 H, Beaumont A-L, Raillon L-A, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136:2290\u20135. https:\/\/doi.org\/10.1182\/blood.2020008423.","journal-title":"Blood"},{"key":"1821_CR20","doi-asserted-by":"publisher","first-page":"ofab335","DOI":"10.1093\/ofid\/ofab335","volume":"8","author":"P Luitel","year":"2021","unstructured":"Luitel P, Vais D, Gidron A. Successful treatment of persistent coronavirus disease 2019 infection in a patient with hypogammaglobulinemia with REGN-COV2: a case report. Open Forum Infect Dis. 2021;8:ofab335. https:\/\/doi.org\/10.1093\/ofid\/ofab335.","journal-title":"Open Forum Infect Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-022-01821-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T10:15:21Z","timestamp":1653905721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-022-01821-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1821"],"URL":"https:\/\/doi.org\/10.1007\/s15010-022-01821-y","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"15 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors reports any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethikkommission Ostschweiz, Scheibenackerstrasse 4, CH-9000 St. Gallen approved this case series. Project-ID 2021-00349 EKOS 21\/027.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent to the submission of the case report to the journal was obtained from patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}